Cadila Pharma launches generic sitagliptin versions to treat uncontrolled type 2 diabetes

The two generic drugs have been launched under the brand names Jankey & Sitenali.

Ahmedabad, 4^th August 2022: Ahmedabad-based Cadila Pharmaceuticals, one of the oldest and largest privately-held drug manufacturers in the country, has launched the generic versions of sitagliptin in India under the brand names Jankey & Sitenali to address type 2 diabetes.

Sitagliptin is a drug from the class of DPP-4 inhibitors, and a one-of-its-kind drug for the treatment of high glucose levels in the blood, also known as hyperglycaemia. High blood glucose can lead to life-threatening complications such as atherosclerosis, stroke, heart attack, retinopathy, neuropathy and nephropathy.

According to a recently published report, approximately 7.7 core people in India are suffering from diabetes. Metformin is presently the drug of choice for controlling blood glucose levels, but in the majority of the patients, it either does not provide optimum control or is not tolerated.

Cadila Pharmaceuticals, a pioneer in Vitamin D3 supplements and a legacy of 50 years in offering affordable range of cardiovascular medicines, has made a foray into the diabetes care segment with the launch of Sitenali and Jankey, having cardio-safe gliptin sitagliptin. It has also launched a potent combination of Sitagliptin and Metformin and branded it as Jankey M.

“Diabetes is a key focus area for Cadila Pharmaceuticals. With the launch of Sitenali and Jankey, we aim to provide an effective and high-quality but affordable medicine in India to treat diabetes,” said Jawed Zia, CEO, Cadila Pharmaceuticals.

Sitagliptin has a strong clinical profile and the potential to revolutionise the treatment of type 2 diabetes for millions of people who do not achieve the targeted blood sugar level with currently available anti-diabetic medications. It delivers unprecedented HbA1c control, weight neutral with a well-established CV safety profile and nominal risk of hypoglycaemia compared to other DPP-4 inhibitors class of drug.

Likewise, Jankey will transform diabetes management demonstrating Cadila Pharmaceuticals’ dedication to continuous patient care through affordable modern medicines.

“We launched Jankey and Sitenali in July and both are widely available across the country. More than 5,000 diabetologists, endocrinologists, cardiologists, and physicians have already started recommending the drug. Our core values are reflected in our endeavours to create and facilitate life-saving healthcare solutions”, Mr. Zia further added.